Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

@article{Lincoff2014EffectOA,
  title={Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.},
  author={Abraham Michael Lincoff and Jean-Claude Tardif and Gregory G. Schwartz and Stephen J Nicholls and Lars Ryd{\'e}n and Bruce Neal and Klas Malmberg and Hans Wedel and John B Buse and Robert R. Henry and Arlette Weichert and Ruth Cannata and Anders Svensson and Dietmar Volz and Diederick E. Grobbee},
  journal={JAMA},
  year={2014},
  volume={311 15},
  pages={1515-25}
}
IMPORTANCE No therapy directed against diabetes has been shown to unequivocally reduce the excess risk of cardiovascular complications. Aleglitazar is a dual agonist of peroxisome proliferator-activated receptors with insulin-sensitizing and glucose-lowering actions and favorable effects on lipid profiles. OBJECTIVE To determine whether the addition of aleglitazar to standard medical therapy reduces cardiovascular morbidity and mortality among patients with type 2 diabetes mellitus and a… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 69 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 60 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

HPS2-THRIVE: randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with preexisting cardiovascular disease

  • Armitage J. Group H-TC
  • Presented at: American College of Cardiology…
  • 2013

Similar Papers

Loading similar papers…